Push for Localization of Next-Generation Cancer Treatment 'Actinium-225'
The localization of 'Actinium-225,' a radioisotope known to be the most potent agent in recent cancer treatment, is being pursued in earnest. Actinium-225 is gaining significant attention as a next-generation cancer therapy due to its ability to precisely target and destroy only cancer cells.
Until now, the global supply of Actinium-225 has been insufficient, creating difficulties in the development of treatments. In response, domestic researchers and relevant institutions are focusing on developing production processes to secure a stable supply chain and achieve technological independence.
If this localization is successful, it is expected that domestic cancer patients will be able to receive state-of-the-art treatment more quickly and affordably. Furthermore, it will serve as an opportunity to reduce reliance on foreign sources and further enhance the competitiveness of domestic medical technology.
The government and related industries plan to continue providing active support for the construction of Actinium-225 production facilities and the training of specialized personnel. We look forward to this technology being introduced into actual clinical settings, significantly improving the treatment environment for cancer patients.